PF-03654746

• UNSPSC Description:

  PF-03654746 is a potent and selective histamine H3 receptor antagonist with high brain penetration. PF-03654746 reduces allergen-induced nasal symptoms, might be a novel therapeutic strategy to further explore allergic rhinitis[1]. PF-03654746 improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD)[2].

• Target Antigen:

  Histamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Inflammation/Immunology; Neurological Disease; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/pf-03654746.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@H]1C[C@@](C2=CC=C(CN3CCCC3)C(F)=C2)(F)C1)NCC

• Molecular Weight:

  322.39

• References & Citations:

  [1]Stokes JR, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012 Feb;129(2):409-12, 412.e1-2.|[2]Brioni JD, et al. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther. 2011 Jan;336(1):38-46.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  935840-31-6